Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

about

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q55360477

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Patient-reported outcomes from ...... nts with rheumatoid arthritis.

@en

Patient-reported outcomes from ...... nts with rheumatoid arthritis.

@nl

type

Item

label

Patient-reported outcomes from ...... nts with rheumatoid arthritis.

@en

Patient-reported outcomes from ...... nts with rheumatoid arthritis.

@nl

prefLabel

Patient-reported outcomes from ...... nts with rheumatoid arthritis.

@en

Patient-reported outcomes from ...... nts with rheumatoid arthritis.

@nl

P1476

Patient-reported outcomes from ...... nts with rheumatoid arthritis.

@en

P2093

Chieh-I Chen

http://www.w3.org/2001/XMLSchema#string

Clare W J Proudfoot

http://www.w3.org/2001/XMLSchema#string

Erin K Mangan

http://www.w3.org/2001/XMLSchema#string

Hubert van Hoogstraten

http://www.w3.org/2001/XMLSchema#string

Janet van Adelsberg

http://www.w3.org/2001/XMLSchema#string

Matthew Reaney

http://www.w3.org/2001/XMLSchema#string

Sophie Guillonneau

http://www.w3.org/2001/XMLSchema#string

Toshio Kimura

http://www.w3.org/2001/XMLSchema#string

Vibeke Strand

http://www.w3.org/2001/XMLSchema#string

Yong Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI)

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

Patient-reported outcomes and their role in the assessment of rheumatoid arthritis.

Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

P2888

s13075-018-1614-z

P304

129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-018-1614-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gerd-Rüdiger Burmester

Laure Gossec

P577

2018-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104991075

http://www.w3.org/2001/XMLSchema#string

P698

29921318

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

phase III clinical trial

P932

6009058

http://www.w3.org/2001/XMLSchema#string